<div class="docx-content">
<h3 class="text-lg font-semibold mt-6 mb-3"><strong>Cryptococcus </strong></h3><h4 class="text-base font-semibold mt-4 mb-2"><strong>1. Taxonomy &amp; Nomenclature</strong></h4><table><tr><td><p><strong>Species complex</strong></p></td><td><p><strong>Varieties / Serotypes</strong></p></td><td><p><strong>Usual host status</strong></p></td><td><p><strong>Key points for exam</strong></p></td></tr><tr><td><p><strong>C. neoformans</strong></p></td><td><p>var. <em>grubii</em> (A) — 95 % of isolates; var. <em>neoformans</em> (D)</p></td><td><p>Opportunist</p></td><td><p>Worldwide; pigeon guano &amp; decaying wood reservoirs</p></td></tr><tr><td><p><strong>C. gattii</strong></p></td><td><p>Serotypes B &amp; C</p></td><td><p>“Primary” pathogen</p></td><td><p>Tropical/sub-tropical (Eucalyptus) but emergent in Canada &amp; PNW USA temperate regions</p></td></tr><tr><td><p><strong>Other spp.</strong> </p><p>(<em>C. albidus, </em></p><p><em>C. laurentii,</em> etc.)</p></td><td><p>—</p></td><td><p>Rare opportunists</p></td><td><p>Often device-associated or profound T-cell immunodeficiency</p></td></tr></table><p><em>► Exam tip</em>: C. <em>neoformans</em> vs C. <em>gattii</em> separation on <strong>CGB agar</strong> (blue colour = <em>gattii</em>).</p><p>Extra point	:	</p><p>Animal reservoir &amp; (rare) zoonosis – dogs, cats, koalas; animal-to-human transmission documented, though exceptional.</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>2. Morphology &amp; Basic Lab Features</strong></h4><ul><li>Encapsulated, round/oval basidiomycete yeasts; narrow-necked budding.</li><li><strong>Urease-positive</strong>, non-fermentative; produce melanin on bird-seed agar.</li><li>Mucicarmine / Alcian blue stain capsule in tissue; <strong>India ink</strong> gives clear halo in CSF. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>3. Virulence Factors (memorise capsule-melanin-laccase pentad)</strong></h4><table><tr><td><p><strong>Factor</strong></p></td><td><p><strong>Function / exam pearl</strong></p></td></tr><tr><td><p><strong>Polysaccharide capsule (GXM &amp; GXMGal)</strong></p></td><td><p>Anti-phagocytic, anti-oxidative, prevents desiccation</p></td></tr><tr><td><p><strong>Melanin</strong> (via laccase)</p></td><td><p>UV protection, drug resistance, environmental survival</p></td></tr><tr><td><p><strong>Proteinases &amp; phospholipases</strong></p></td><td><p>Tissue invasion, nutrient acquisition</p></td></tr><tr><td><p><strong>Urease</strong></p></td><td><p>Aids blood–brain crossing</p></td></tr><tr><td><p><strong>MATα mating type</strong></p></td><td><p>More common &amp; more virulent than MATa</p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>4. Epidemiology &amp; Risk Factors</strong></h4><table><tr><td><p><strong>Species</strong></p></td><td><p><strong>Geography</strong></p></td><td><p><strong>Classic host</strong></p></td><td><p><strong>Emerging risks</strong></p></td></tr><tr><td><p><em>C. neoformans</em> var. <em>grubii</em></p></td><td><p>Global</p></td><td><p>Advanced HIV, transplant</p></td><td><p>DM, malignancy</p></td></tr><tr><td><p>var. <em>neoformans</em></p></td><td><p>Europe (≈30 % isolates)</p></td><td><p>As above</p></td><td><p>—</p></td></tr><tr><td><p><em>C. gattii</em></p></td><td><p>Tropics/Sub-tropics, Vancouver Isl., PNW USA</p></td><td><p>Immunocompetent adults</p></td><td><p>Cancer, idiopathic CD4 lymphopenia, chronic steroids, smoking</p></td></tr><tr><td><p>Non-neoformans/gattii</p></td><td><p>Worldwide</p></td><td><p>Profound CD4 depression, catheters</p></td><td><p>—</p></td></tr></table><p><em>Global burden</em>: ≈1 million cases/yr cryptococcal meningitis in HIV (&gt;70 % sub-Saharan Africa). </p><p>Disease in children is very uncommon (≈ 1 % of AIDS cases)</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>5. Pathogenesis &amp; Disease Spectrum</strong></h4><ul><li>Acquired by <strong>inhalation</strong> → pulmonary infection ± latent foci.</li><li><strong>Dissemination</strong> (especially to CNS) during cell-mediated immunosuppression or via urease-mediated BBB transit.</li><li><em>C. gattii</em>: tendency to form large <strong>cryptococcomas</strong> in lung/brain; morbidity high, mortality lower vs <em>neoformans</em>. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>6. Clinical Presentation (species-independent)</strong></h4><ol><li><strong>CNS</strong> – meningitis/meningo-encephalitis, raised ICP.</li><li><strong>Pulmonary</strong> – nodules, mass lesions, pneumonia.</li><li><strong>Bloodstream</strong> – fungaemia in severe immunosuppression.</li><li><strong>Other</strong> – skin, bone, prostate, ocular. </li></ol><h4 class="text-base font-semibold mt-4 mb-2"><strong>7. Diagnostic Approach</strong></h4><table><tr><td><p><strong>Step</strong></p></td><td><p><strong>Key tests</strong></p></td><td><p><strong>FRCPath nuances</strong></p></td></tr><tr><td><p><strong>Direct microscopy</strong></p></td><td><p>India ink (CSF, urine), tissue histology stains</p></td><td><p>Less sensitive in low-burden disease</p></td></tr><tr><td><p><strong>Antigen detection</strong></p></td><td><p>Serum/CSF <strong>CrAg LFA</strong> (IMMY) – rapid, high Sn/Sp for <em>neoformans/gattii</em></p></td><td><p>False + rare; NOT reliable for other species</p></td></tr><tr><td><p><strong>Culture</strong></p></td><td><p>Sabouraud agar; bird-seed (melanin) &amp; <strong>CGB</strong> for speciation</p></td><td><p>gatii = blue</p></td></tr><tr><td><p><strong>Identification</strong></p></td><td><p>rDNA ITS / D1-D2 sequencing or <strong>MALDI-TOF-MS</strong> (database-dependent)</p></td><td></td></tr><tr><td><p><strong>Susceptibility</strong></p></td><td><p>CLSI broth microdilution; all intrinsically <strong>echinocandin-resistant</strong></p></td><td></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>8. Treatment &amp; Prophylaxis</strong></h4><table><tr><td><p><strong>Setting</strong></p></td><td><p><strong>Induction (2 weeks)</strong></p></td><td><p><strong>Consolidation / Maintenance</strong></p></td><td><p><strong>Notes</strong></p></td></tr><tr><td><p><em>C. neoformans</em> / <em>C. gattii</em> meningitis</p></td><td><p><strong>Liposomal amphotericin B</strong> 5mg/kg +  flucytosine 25mg/kg  PO QDS</p></td><td><p>Fluconazole 400mg OD ≥8 wks then  200mg ≥12 m maintenance (lifelong if relapse risk)</p></td><td><p>Monitor ICP; HAART integration @ 2 wks improves outcome in HIV</p></td></tr><tr><td><p>Non-neoformans/gattii</p></td><td><p>Amphotericin B until improvement → step-down fluconazole <em>if susceptible</em></p></td><td><p>Tailor to site/severity; device removal may suffice in mild disease</p></td><td><p>Higher MICs to 5-FC &amp; azoles reported</p></td></tr></table><p><em>Resistance alerts</em>: emerging fluconazole, amphotericin B, 5-FC resistance after prolonged therapy or prophylaxis. </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>9. High-Yield Exam Pearls</strong></h4><ol><li><strong>CGB agar blue = <em>gattii</em></strong> (g for <em>gattii</em> and <strong>g</strong>lycine).</li><li>Urease positivity plus encapsulation distinguishes Cryptococcus from other yeasts.</li><li><strong>CrAg LFA</strong> is validated for serum/CSF/urine; limited for non-neoformans/gattii.</li><li>Always consider raised opening pressure (&gt;25 cm H₂O) in cryptococcal meningitis → serial lumbar punctures.</li><li>Intrinsic <strong>echinocandin resistance</strong>—never suitable for treatment.</li><li><em>C. gattii</em> outbreaks linked to non-Eucalyptus trees in Canada (Douglas Fir).</li><li>MATα isolates predominate in clinical disease.</li><li>Mortality without therapy ~100 %; early induction therapy critical. </li></ol><p><strong>Mnemonic for virulence factors</strong> – <strong>“CLaMPU”</strong>: <strong>C</strong>apsule, <strong>La</strong>ccase (melanin), <strong>M</strong>elanin, <strong>P</strong>hospholipase/proteinase, <strong>U</strong>rease.</p>
</div>